Subscribe

EuBiologics Co., Ltd. (206650.KQ)

KRW8,170.00 +310.00 (+3.94%)
KR KOE Healthcare Drug Manufacturers - Specialty & Generic
Address Bomnal-A-Chim B/D
Seoul, KR
CEO Yeong-Ok Baik
Website eubiologics.com
IPO 2017-01-24
ISIN KR7206650004

Explore sections of this company profile

Description

Established in 2010 and based in Seoul, South Korea, EuBiologics Co., Ltd. is a biopharmaceutical company dedicated to developing and supplying essential vaccines for epidemics and antibiotic resistance within the country. Its product portfolio includes Euvchol, an oral vaccine for cholera prevention, and CRM197, a diphtheria toxin-mutant vaccine. Beyond its vaccine offerings, the company provides comprehensive, customized services for biopharmaceuticals derived from mammalian and microbial cells, guiding clients through various project stages such as cell line development, GMP production, validation, and regulatory assistance. EuBiologics operates advanced facilities equipped for the manufacturing of protein-based therapeutics and antibodies, with a particular specialization in recombinant biological products and antibody treatments. Additionally, the company offers expertise in process, formulation, and analytical method development, provides licensing consulting, and delivers a range of contract testing services, including lot release, stability, raw material, and method validation.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW8,170.00 +310.00 (+3.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
274.4K
Beta
0.18
Float Shares
29.14M
Free Float %
79.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.67% -12.28% -21.88% -33.11% -21.51% -12.36% -23.25% +29.03% -78.95% +97.24% +97.24%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
8,170.00
Ratings Trend (MoM)
Rating 2025-10 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
6.60
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +55.4% ★ Q1'26: -60.4% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +114.7% ★ Q1'26: -76.7% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +19.1% ★ Q1'26: +15.4% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +40.7% ★ Q1'26: +14.1% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +44.4% ★ Q1'26: +8.7% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.5% Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.06× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.36) × ERP
WACC = 99% × Ke + 1% × Kd (24.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 8,170.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
4.84B
est: 10.50B (-53.9%)
11.57B
est: 12.00B (-3.6%)
24.89B
est: 24.45B (+1.8%)
33.07B
est: 33.50B (-1.3%)
28.49B
est: 23.80B (+19.7%)
39.38B
est: 34.50B (+14.2%)
55.47B
est: 41.80B (+32.7%)
69.37B
est: 69.20B (+0.2%)
96.04B
est: 101.70B (-5.6%)
149.20B
est: 156.40B (-4.6%)
139.30B
139.30B – 139.30B
-10.9% YoY
129.80B
129.80B – 129.80B
-6.8% YoY
EBITDA
-4.54B
est: -2.62B (-73.2%)
-2.74B
est: -3.00B (+8.7%)
3.30B
est: -6.11B (+154.1%)
2.67B
est: -8.37B (+131.9%)
-52.51B
est: -5.94B (-783.3%)
-23.42B
est: -8.62B (-171.7%)
5.37B
est: -10.44B (+151.5%)
-4.39B
est: -17.28B (+74.6%)
29.67B
est: 4.51B (+558.5%)
70.66B
est: 6.93B (+919.6%)
6.17B
6.17B – 6.17B
-10.9% YoY
5.75B
5.75B – 5.75B
-6.8% YoY
EBIT
-6.13B
est: -3.77B (-62.6%)
-4.48B
est: -4.31B (-4.1%)
1.34B
est: -8.78B (+115.3%)
-303.19M
est: -12.02B (+97.5%)
-58.46B
est: -8.54B (-584.3%)
-8.33B
est: -12.38B (+32.8%)
-2.51B
est: -15.00B (+83.3%)
-13.56B
est: -24.84B (+45.4%)
19.60B
est: -7.96B (+346.2%)
60.66B
est: -12.24B (+595.6%)
-10.90B
-10.90B – -10.90B
+10.9% YoY
-10.16B
-10.16B – -10.16B
+6.8% YoY
Net Income
-6.70B
est: -4.90B (-36.7%)
-4.72B
est: -5.56B (+15.2%)
3.78B
est: 10.71B (-64.7%)
-881.62M
est: 1.23B (-171.4%)
-60.13B
est: -7.09B (-747.9%)
-27.57B
est: 9.67B (-385.2%)
-1.10B
est: 10.06B (-110.9%)
-13.88B
est: -4.40B (-215.6%)
18.99B
est: 16.87B (+12.6%)
41.26B
est: 50.79B (-18.8%)
38.51B
38.51B – 38.51B
-24.2% YoY
35.54B
35.54B – 35.54B
-7.7% YoY
SGA
1.81B
est: 478.63M (+278.6%)
2.42B
est: 547.01M (+341.5%)
3.28B
est: 1.11B (+194.4%)
4.85B
est: 1.53B (+217.8%)
1.28B
est: 1.08B (+18.2%)
1.60B
est: 1.57B (+1.7%)
3.18B
est: 1.91B (+67.1%)
3.43B
est: 3.15B (+8.8%)
3.40B
est: 4.35B (-21.9%)
4.61B
est: 6.69B (-31.1%)
5.96B
5.96B – 5.96B
-10.9% YoY
5.55B
5.55B – 5.55B
-6.8% YoY
EPS
-385.87
est: -134.39 (-187.1%)
-188.18
est: -152.28 (-23.6%)
145.87
est: 293.43 (-50.3%)
-32.35
est: 33.84 (-195.6%)
-2,146.27
est: -194.33 (-1,004.4%)
-777.82
est: 264.91 (-393.6%)
-30.19
est: 275.55 (-111.0%)
-380.79
est: -120.50 (-216.0%)
523.82
est: 460.00 (+13.9%)
1,127.16
est: 1,385.00 (-18.6%)
1,050.00
1,050.00 – 1,050.00
-24.2% YoY
969.00
969.00 – 969.00
-7.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-28 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-27 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-26 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-22 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-21 B 3/5 1/5 5/5 5/5 1/5 2/5 2/5
2026-05-20 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-19 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-18 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-15 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-14 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-13 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-12 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-11 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-08 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-07 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-06 A- 4/5 1/5 5/5 5/5 3/5 3/5 3/5
2026-05-04 A- 4/5 1/5 5/5 5/5 3/5 4/5 3/5
2026-04-30 A- 4/5 1/5 5/5 5/5 3/5 4/5 3/5
2026-04-29 A- 4/5 1/5 5/5 5/5 3/5 4/5 3/5
2026-04-28 A- 4/5 1/5 5/5 5/5 3/5 4/5 3/5
2026-04-27 A- 4/5 1/5 5/5 5/5 3/5 4/5 3/5
2026-04-24 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-23 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-22 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-21 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-20 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-17 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5
2026-04-16 B+ 3/5 1/5 5/5 5/5 2/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
32.08B
OE per share TTM
870.61
Owner's Yield
8.74%
Maintenance CapEx ratio
694.57%
Maint CapEx / Avg PPE
105.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 30 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Kodex Healthcare 266420.KS 0.21% 96.6K 0.09%
2 Samsung Kodex Fn Growth ETF 325010.KS 0.02% 24.5K 0.30%
3 Schwab International Small-Cap Equity ETF SCHC 0.01% 310.0K 0.06%
4 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 683.8K 0.06%
5 Dimensional - Emerging Markets Value ETF DFEV 0.00% 74.3K 0.46%
6 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.00% 10.2K 0.56%
7 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 18.7K 0.44%
8 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 205.3K 0.39%
9 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 195.0K 0.29%
10 Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO 0.00% 3.8K 0.22%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
187.81M
Shares Outstanding
36.62M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Chan-kyu Lee Vice President & Head of Research and Development — male
Kyeong-Ho Min Vice President & Head of Production — male
Tae-Young Heo Chief Executive Officer, Head of Management Administration & Director — —
Yeong-Ok Baik Chief Executive Officer, Head of Production, Quality, R&D and Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic